As shown in Fig. 4d, lapatinib alone activated the AKT and ERK pathways in a dose-dependent manner (increased phosphorylated AKT and phosphorylated ERK1/2 levels), but it had no effect on the Src pathway in NPC cells. The gene discussed is AKT1; the disease is nasopharyngeal carcinoma.